J Korean Orthop Assoc.  2013 Jun;48(3):180-184. 10.4055/jkoa.2013.48.3.180.

Medical Treatment of Atypical Femoral Fracture

• Ha YC
• Lee YK
• Min BW

• KMID: 2106670
• DOI: http://doi.org/10.4055/jkoa.2013.48.3.180

Abstract

Unlike typical hip fractures, atypical femoral fractures occur at subtrochanteric or diaphyseal area. Characteritics of atypical femoral fractures include their location in the subtrochanteric region and femoral shaft, transverse or short oblique orientation, minimal or no associated trauma, a medial spike when the fracture is complete, and absence of comminution. Most important treatment of atypical femoral fractures is a rigid internal fixation. However, an atypical femoral fracture resulting from long-term use of bisphosphonate might occur as delayed union or nonunion. Some case reports on effectiveness of bone-forming agents in atypical femoral fractures have been reported. According to the reported researches, parathyroid hormone and strontium ranelate are known to be effective in rapid recovery of osteoporosis and fracture. However, additional well-designed research on effectiveness of bone-forming agents in atypical femoral fractures will be necessary.

Keyword

femur; atypical fracture; bisphosphonate; medical treatment

MeSH Terms

Femoral Fractures
Femur
Hip Fractures
Organometallic Compounds
Orientation
Osteoporosis
Parathyroid Hormone
Strontium
Thiophenes
Organometallic Compounds
Parathyroid Hormone
Strontium
Thiophenes

Reference

1. Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189–1199.

2. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011; 49:34–41.

3. Kim KW, Kim SH, Park YG, Ha YC. Bone biopsy of atypical subtrochanteric fracture in patient with prolonged bisphosphonate therapy: a case report. Korean J Bone Metab. 2011; 18:131–135.

4. Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res. 2010; 468:3393–3398.

5. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010; 92:679–686.

6. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int. 2009; 84:159–170.

7. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434–1441.

8. Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1-84). Drugs. 2006; 66:2371–2381.

9. Sibai T, Morgan EF, Einhorn TA. Anabolic agents and bone quality. Clin Orthop Relat Res. 2011; 469:2215–2224.

10. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350:459–468.

11. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90:2816–2822.

12. Ellegaard M, Jørgensen NR, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int. 2010; 87:1–13.

13. Yu CT, Wu JK, Chang CC, Chen CL, Wei JC. Early callus formation in human hip fracture treated with internal fixation and teriparatide. J Rheumatol. 2008; 35:2082–2083.

14. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:404–414.

15. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011; 93:1583–1587.

16. Oteo-Alvaro A, Moreno E. Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34): a case report. J Shoulder Elbow Surg. 2010; 19:e22–e28.

17. Tarantino U, Celi M, Saturnino L, Scialdoni A, Cerocchi I. Strontium Ranelate and bone healing: report of two cases. Clin Cases Miner Bone Metab. 2010; 7:65–68.

18. Habermann B, Kafchitsas K, Olender G, Augat P, Kurth A. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int. 2010; 86:82–89.

19. Quesada-Gómez JM, Muschitz C, Gómez-Reino J, Greisen H, Andersen HS, Dimai HP. The effect of PTH (1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos Int. 2011; 22:2529–2537.

20. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011; 96:2675–2680.